Goodwin Procter advised Forge Global on the deal. Forge Global announced its definitive merger agreement with Motive Capital Corp (NYSE: MOTV.U) sponsored by affiliates of Motive Partners....
Forge Global’s $2 Billion Merger with Motive Capital Corp
Laronde’s $440 Million Series B Financing
Goodwin Procter advised Laronde on the deal. Laronde announced its $440 million Series B Financing to advance the development of its eRNA platform and a broad pipeline...
Vigil Neuroscience’s $90 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Vida Ventures on the deal while Goodwin Procter represented Vigil Neuroscience. Vigil Neuroscience, a biotechnology company harnessing the power of...
GeneWerk’s Merger with Protagen Protein Services
Goodwin Procter advised GeneWerk on the deal. GeneWerk announced its merger with Protagen Protein Services. GeneWerk, an Ampersand portfolio company, is a cell and gene therapy testing...
VRChat’s $80 Million Series D Investment Round
Goodwin Procter LLP advised VRChat on the deal. VRChat announced its $80 Million Series D investment round. The financing was led by Anthos Capital, alongside existing investors...
Symphony’s Acquisition of Cloud9 Technologies
Goodwin Procter LLP advised Symphony on the deal while Wilmer Cutler Pickering Hale and Dorr represented Cloud9 Technologies. Symphony announced its acquisition of Cloud9 Technologies. Symphony is...
Valo Health’s $2.8 Billion Merger with Khosla Ventures Acquisition Co.
Goodwin Procter LLP advised Valo Health on the deal, while Latham & Watkins LLP represented Khosla Ventures Acquisition Co. Valo Health announced its definitive merger agreement with...
Neuroelectrics’ $17.5 Million Series A Financing
Goodwin Procter LLP advised Neuroelectrics on the deal. Neuroelectrics announced its $17.5 million Series A financing led by Morningside Ventures. Neuroelectrics is developing a therapeutic platform that...
ElevateBio’s $525 Million Series C Financing
Goodwin Procter LLP advised ElevateBio on the deal. ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced it...
Monte Rosa Therapeutics’ $95 Million Series C Financing
Goodwin Procter LLP advised Monte Rosa Therapeutics on the deal. Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing...